中山醫學大學機構典藏 CSMUIR:Item 310902500/23520
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 17918/22933 (78%)
造訪人次 : 7437880      線上人數 : 58
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋


    請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23520


    題名: Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
    作者: Liu, CH;Chen, CY;Su, WW;Liu, CJ;Lo, CC;Huang, KJ;Chen, JJ;Tseng, KC;Chang, CY;Peng, CY;Shih, YL;Huang, CS;Kao, WY;Yang, SS;Tsai, MC;Wu, JH;Chen, PY;Su, PY;Hwang, JJ;Fang, YJ;Lee, PL;Tseng, CW;Lee, FJ;Lai, HC;Hsieh, TY;Chang, CC;Chang, CH;Huang, YJ;Kao, JH
    關鍵詞: Hepatitis;Chronic;Antiviral agents;Sofosbuvir;Ribavirin;Liver cirrhosis
    日期: 2021
    上傳時間: 2022-08-05T09:38:36Z (UTC)
    出版者: KOREAN ASSOC STUDY LIVER
    ISSN: 2287-2728
    摘要: Background/Aims: Real-world studies assessing the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV) for Child-Pugh B/C hepatitis C virus (HCV)-related cirrhosis are limited. Methods: We included 107 patients with Child-Pugh B/C HCV-related cirrhosis receiving SOF/VEL plus RBV for 12 weeks in Taiwan. The sustained virologic response rates at off-treatment week 12 (SVR12) for the evaluable population (EP), modified EP, and per-protocol population (PP) were assessed. The safety profiles were reported. Results: The SVR12 rates in the EP, modified EP and PP were 89.7% (95% confidence interval [CI], 82.5-94.2%), 94.1% (95% CI, 87.8-97.3%), and 100% (95% CI, 96.2-100%). Number of patients who failed to achieve SVR12 were attributed to virologic failures. The SVR12 rates were comparable regardless of patient characteristics. One patient discontinued treatment because of adverse events (AEs). Twenty-four patients had serious AEs and six died, but none were related to SOF/VEL or RBV. Among the 96 patients achieving SVR12, 84.4% and 64.6% had improved Child-Pugh and model for end stage liver disease (MELD) scores. Multivariate analysis revealed that a baseline MELD score >_15 was associated with an improved MELD score of >_3 (odds ratio, 4.13; 95% CI, 1.16-14.71; P=0.02). Patients with chronic kidney disease (CKD) stage 1 had more significant estimated glomerular filtration rate declines than patients with CKD stage 2 (-0.42 mL/min/1.73 m(2)/month; P=0.01) or stage 3 (-0.56 mL/min/1.73 m(2)/month; P<0.001). Conclusions: SOF/VEL plus RBV for 12 weeks is efficacious and well-tolerated for Child-Pugh B/C HCV-related cirrhosis.
    URI: http://dx.doi.org/10.3350/cmh.2021.0155
    https://www.webofscience.com/wos/woscc/full-record/WOS:000706507200008
    https://ir.csmu.edu.tw:8080/handle/310902500/23520
    關聯: CLINICAL AND MOLECULAR HEPATOLOGY ,2021,v27,issue 4, P575-588
    顯示於類別:[中山醫學大學研究成果] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML261檢視/開啟


    SFX Query

    在CSMUIR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋